TLR-9 agonists augment function of antigen-specific CD8+ T cells and, in melanoma, have shown evidence of immunogenicity in combination with cancer vaccines and promising activity as a single-agent or in combination with anti-PD-1 blockade in PD-1 naïve and PD-1-refractory patients. The gene discussed is CD8A; the disease is melanoma.